Wave Life Sciences (WVE) Cash from Investing Activities (2014 - 2026)
Wave Life Sciences (WVE) posted Cash from Investing Activities of -$438000.0 for Q1 2026, down 43900.0% on a QoQ basis from $1000.0 in Q4 2025, and down 165.45% year-over-year from $669166.7 in Q1 2025.
Wave Life Sciences (WVE) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Wave Life Sciences' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$438000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 165.45% year-over-year to -$438000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$991000.0 (down 44.46% YoY) and the FY2025 annual result came in at -$718000.0, up 23.45% from the prior year.
- Cash from Investing Activities was -$438000.0 for Q1 2026 at Wave Life Sciences, down from $1000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $24.8 million in Q4 2022 and bottomed at -$50.2 million in Q1 2022.
- A 5-year average of -$262588.2 and a median of -$248000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 165700.0% in 2022, while the deepest fall reached 46388.89% in 2022.
- Wave Life Sciences' Cash from Investing Activities stood at $24.8 million in 2022, then tumbled by 101.43% to -$356000.0 in 2023, then surged by 75.84% to -$86000.0 in 2024, then surged by 101.16% to $1000.0 in 2025, then tumbled by 43900.0% to -$438000.0 in 2026.
- Business Quant data shows WVE's Cash from Investing Activities at -$438000.0 in Q1 2026, $1000.0 in Q4 2025, and -$248000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Wave Life Sciences | 1.19 Bn | 647.41 Mn | - | -438,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -438,000.00 |
| Mar 31, 2026 | -438,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Sep 30, 2025 | -248,000.00 |
| Jun 30, 2025 | -306,000.00 |
| Jun 30, 2025 | -306,000.00 |
| Mar 31, 2025 | -165,000.00 |
| Mar 31, 2025 | -165,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Sep 30, 2024 | -383,000.00 |
| Sep 30, 2024 | -383,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Dec 31, 2023 | -356,000.00 |
| Dec 31, 2023 | -356,000.00 |